Plus   Neg

NMRD Up 60% In 2 Days, TLRY Keeps Hitting New Highs, MNLO Awaits Data In Oct.

pharma 022318 13sep18 lt

The following are some of today's top gainers in the pharma/biotech sector.

1. Nemaura Medical Inc. (NMRD)

Gained 19.93% to close Thursday's (Sep.13) trading at $3.43. This is the second straight day of double-digit gain for the stock.

Recent event:

Yesterday, the Company reported positive data from an interim analysis of the first of a number of planned studies in support of a submission to the FDA for approval of its SugarBEAT product, which sent the stock up 30% to $2.86.

SugarBEAT is a non-invasive affordable and flexible Continuous Glucose Monitor for use by persons with diabetes and pre-diabetics. The completion of the U.S. study evaluating SugarBEAT and FDA submission is expected in Q1 2019.

The product is expected to be launched in the UK in the coming months.

2. Xtant Medical Holdings Inc. (XTNT)

Gained 14.50% to close Thursday's trading at $4.58.

News: No news

Recent event:

The Company reported Q2 financial results on August 7.

Net loss incurred in the second quarter 2018 was $5.0 million or $0.38 per share compared to a loss of $9.7 million or $6.43 per share in the same period of the prior year. Revenue for the second quarter of 2018 was $18.7 million, down from $21.4 million compared to the same period of the prior year. Gross margin for the second quarter of 2018 was 66.6% compared to 63.2% during the second quarter of 2017.

As of June 30, 2018, the Company had $6 million of cash and cash equivalents.

3. Tilray Inc. (TLRY)

Gained 14.11% to close Thursday's trading at $119.76.

News: The Company has received necessary regulatory permits in Canada and Germany to export medical cannabis flower for distribution to German patients.

The export of Tilray's whole flower medical cannabis products will make Tilray the first and only medical cannabis company with a differentiated product offering of both full-spectrum oils and whole flower, including some of the highest potency products available in the German medical market. Certain patient populations with specialized conditions require higher potency THC medical cannabis as treatment.

These patients will now have access to products that were previously unavailable to them in this market.

Last October, Tilray was permitted to legally import full-spectrum medical cannabis extract products into Germany for nationwide distribution through pharmacies.

4. Checkpoint Therapeutics Inc. (CKPT)

Gained 14.90% to close Thursday's trading at $4.55.

News: No news

Recent event:

On September 6, the Company announced positive preliminary safety and efficacy data from an ongoing Phase I/II clinical trial of CK-101 being evaluated in advanced non-small cell lung cancer.

Near-term Catalysts:

-- The Phase I/II clinical trial of CK-101 in advanced non-small cell lung cancer will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto on Sept. 24.
-- The Company plans to advance CK-101 towards a pivotal phase III trial next year.

You can find more about CKPT in our report titled "Have You Checked Checkpoint Therapeutics Yet?" posted on August 16.

5. Menlo Therapeutics Inc. (MNLO)

Gained 12.79% to close Thursday's trading at $10.32.

News: No news

Recent events:

-- On January 25, Menlo shares debuted on the Nasdaq Global Select Market at an offering price of $17 each.
-- On April 8, the Company announced that its phase II clinical trial of Serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis, dubbed ATOMIK, MTI-103 study, did not meet its primary or key secondary efficacy endpoints, sending the shares down by 76%.

Near-term Catalysts:

-- Data from a phase II trial of Serlopitant in Refractory Chronic Cough is expected in October 2018.
-- Initiation of a new phase II study of Serlopitant in Chronic Pruritus of unknown origin is anticipated in Q4, 2018.
-- Data from a phase II trial of Serlopitant in Psoriasis is expected in December 2018 or January 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT